GlassScriptPhysician profile
Leo L Shue
NPI 1477544344
$11,063.37
in general payments reported to CMS, 2019-2025
34 companies · $1,144 in 2025
The $1,144 reported for 2025 was less than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,678 · 2020: $746 · 2021: $1,190 · 2022: $1,300 · 2023: $1,117 · 2024: $2,888 · 2025: $1,144.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,138 · Education: $11.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,138.03 |
| Education | $11.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,586.51 | 2019-2025 | Tezspire, Airsupra, Breztri |
| Gilead Sciences, INC. | $1,687.69 | 2019-2025 | Vemlidy, Livdelzi, Yeztugo |
| Glaxosmithkline, LLC. | $1,675.40 | 2019-2025 | Arexvy, Nucala, Trelegy Ellipta |
| Genzyme Corporation | $808.78 | 2019-2024 | |
| Genentech USA, INC. | $578.19 | 2019-2025 | Xolair |
| Regeneron Healthcare Solutions, INC. | $534.52 | 2019-2025 | Dupixent |
| Optinose US, INC. | $338.14 | 2019-2023 | |
| Sunovion Pharmaceuticals INC. | $306.26 | 2019-2022 | |
| Dexcom, INC. | $279.45 | 2023-2024 | Dexcom G7 Gss (161) |
| Eisai INC. | $207.34 | 2024 | |
| Pfizer INC. | $168.33 | 2019-2022 | |
| Abbott Laboratories | $138.37 | 2024 | Freestyle Libre 3 |
| Abbvie INC. | $137.84 | 2022-2023 | Rinvoq |
| Penumbra, INC. | $129.31 | 2019 | |
| Phathom Pharmaceuticals, INC. | $125.00 | 2024 | Voquezna |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Pharmaceuticals, INC. | $124.99 | 2024 | Xelstrym |
| Kaleo, INC. | $118.92 | 2019-2021 | |
| Amgen INC. | $117.70 | 2021-2022 | |
| Grifols USA, LLC | $112.30 | 2021 | |
| Merck Sharp & Dohme LLC | $108.85 | 2021-2025 | Enflonsia |
| Blueprint Medicines Corporation | $104.11 | 2024 | Ayvakit |
| Silk Road Medical, INC. | $97.13 | 2021 | |
| Sanofi Pasteur INC. | $92.00 | 2024 | |
| Novo Nordisk INC | $79.69 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $78.76 | 2019 | |
| Vertos Medical, INC. | $77.74 | 2019 | |
| Mylan Specialty L.P. | $67.24 | 2019 | |
| Electromed, INC. | $41.13 | 2019 | |
| Biomerieux INC | $37.47 | 2019-2020 | |
| Melinta Therapeutics, LLC | $22.96 | 2019 | |
| Philips North America LLC | $22.45 | 2019 | |
| Alk-Abello, INC | $22.23 | 2022 | |
| Uswm, LLC | $19.25 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leo Shue listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.